In conclusion, IM dose escalation represents a valuable option leading, in a vast majority of patients, to optimal cytogenetic and molecular responses in patients with suboptimal cytogenetic responses to frontline IM 400. In patients with primary suboptimal molecular responses, this strategy seems to be less effective and the potential of second-generation tyrosine kinase inhibitors or combination strategies should be investigated to prevent overt resistance.
Genes encoding multiple forms of phospholipase A 2 are expressed in immature forms of human leukemic blasts Phospholipase A 2 (PLA 2 ) catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids to liberate the eicosanoid precursor, arachidonic acid (AA).
1,2 Three distinct families have been documented: low molecular weight soluble forms of PLA 2 (sPLA 2 ); Ca 2 þ -dependent high molecular weight PLA 2 (cPLA 2 ) and Ca 2 þ -independent high molecular weight PLA 2 (iPLA 2 ). The sPLA 2 family is implicated in several biological processes such as inflammation and host defense. 1, 2 Nine isoenzymes have been identified. Among them sPLA 2 -IB is the pancreatic one. sPLA 2 -IIA is constitutively expressed in various organs related to immune response such as bone marrow, spleen and thymus. sPLA 2 -V is found in several immune cells such as macrophage, mast cells and type II helper T cells. sPLA 2 -X is expressed in the digestive tract, immune organs and blood leukocytes. The cPLA 2 family consisted of four members, cPLA 2 -IVA, cPLA 2 -IVB, cPLA 2 -IVC and cPLA 2 -IVD; cPLA 2 -IVA being the central regulator of stimulus-coupled cellular AA release. 1, 2 The iPLA 2 (PLA 2 -VI) plays a major role in phospholipids remodeling.
Eicosanoid products of the cyclooxygenase (COX) and lipoxygenase pathways of AA are important mediators of malignant proliferation. 3 Deregulated PLA 2 activity contributes to the pathogenesis of several malignancies including prostate cancer, ovarian carcinoma and colorectal adenocarcinoma. 1, 2 The COX and lipoxygenase pathways of AA have been recently documented on immature leukemic blasts of patients with acute myeloid (AML) and acute lymphoid (ALL) leukemia. 4, 5 Thus, freshly isolated AML and ALL blasts express COX-1, produce the AA metabolite prostaglandin E 2 , express functional EP 2 receptors and increase their growth in response to exogenously added prostaglandin E 2 . The World Health Organization has proposed a classification system that divides AML into several broad groups: AML with genetic abnormalities, AML with multilineage dysplasia, AML related to earlier chemotherapy or radiation and AML not otherwise specified. The latter group contains a subgroup, AML without maturation, which consisted of the weaker immature blast group. In view of the potentially important oncogenic action of PLA 2 in leukemic proliferation, quantitative PCR was used to determine the PLA 2 mRNAs that were expressed in AML blasts without maturation and ALL blasts.
Blood samples recovered on EDTA were obtained from twenty-one AML patients and ten B-ALL patients at diagnosis according to the Helsinki recommendations. AML patients consisted in a homogeneous group of patients with blasts without signs of maturation and no genetic abnormality. Blood samples with more than 85% blast cells as circulating leukocytes were used. Leukocytosis ranged from 10 to 219 g/l. Immediately after recovery leukemic blasts were isolated by separation on a Ficoll gradient and washed once with Hank's balanced salts solution. The blast purity (498%) was controlled by flow cytometry analysis. Blast viability (495%) was judged by trypan blue exclusion. Blast RNA was immediately extracted with Tripure (Roche GmbH, Mannheim, Germany) and was Figure 1 Quantitative (Q) -PCR analysis of cytosolic phospholipase (PL) A 2 and soluble PLA 2 transcripts in leukemic blasts.Q-PCR was carried out in duplicate by using TaqMan assay reagents according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA, USA) (product references -PLA 2 -IB: Hs00386701-m1; PLA 2 -IIA: Hs00179898-m1; PLA 2 -IID: Hs00173860-m1; PLA 2 -IIF: Hs00224482; PLA 2 -IVA: Hs00233352-m1; PLA 2 -IVB: Hs00979952-m1; PLA 2 -IVC: Hs00234345-m1; PLA 2 -IVD: Hs00603557-m1; PLA 2 -V: Hs00173472-m1; PLA 2 -VI: Hs001/85926-m1; PLA 2 -X: Hs00358567-m1 and PLA 2 -XII: Hs00830106-s1). Gene expression levels were normalized to 18S RNA (product reference Hs99999901-s1). Amounts of various transcripts were compared with sample with the lowest level of transcripts (a patient who was arbitrarily quoted (1). (K) indicates patients with no detectable transcript. Significance was assessed by using the Kruskal-Wallis test followed by a Mann-Whitney U-test. A Bonferroni adjustment indicated a Po0.016 as significant. ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; C, control; ns, non significant. stored at À80 1C until used. As a control group, blood samples were recovered from seven healthy volunteers. Control blood mononuclear cells were recovered and processed exactly as for leukemic blast samples.
In a first set of experiments, we investigated whether mRNAs derived from the four cPLA 2 genes were detected in AML and ALL leukemic blasts. As shown in Figure 1 (left part), mRNAs derived from three of the four cloned cPLA 2 genes are detected in human leukemic blasts. PLA 2 -IVD transcripts were not present at detectable levels in AML and ALL leukemic blasts and in blood mononuclear cells from healthy individuals (data not shown). In contrast, PLA 2 -IVA, PLA 2 -IVB and PLA 2 -IVC were detected. Similar amounts of PLA 2 -IVB and PLA 2 -IVC transcripts were found in AML and ALL blasts and control cells. Both enzymes show little specificity for the sn-2 fatty acid. 1, 2 In contrast, PLA 2 -IVA transcripts were markedly (P ¼ 0.006) reduced in ALL blasts as compared with blood mononuclear cells. PLA 2 -IVA preferentially hydrolyzes phospholipids containing AA at the sn-2 position. PLA 2 -IVA is ubiquitously and constitutively expressed in most cells and tissues. One notable exception is mature B and T cells, which do not contain detectable levels of PLA 2 -IVA. 1 Quantitative PCR analysis shows that PLA 2 -IVA levels were also markedly lowered in immature forms of ALL blasts. The high levels of AA documented in ALL blasts have been earlier related to an elevated D 6 desaturase activity. 6 Low levels of PLA 2 -IVA in ALL blasts might also explain these elevated AA amounts. PLA 2 -VI (iPLA 2 ) transcript levels were higher (P ¼ 0.003) in AML and ALL leukemic blasts. PLA 2 -VI was originally reported to mediate phospholipids remodeling and, thus, to act as a housekeeping protein without significant roles in cell growth. 1, 2 Several recent studies have shown that PLA 2 -VI exhibited roles in cell regulation, growth and death. Especially, one mechanism by which PLA 2 -VI mediates cell growth involves regulation of AA release, p53 and mitogen-activated protein kinase activation. 7 A role for PLA 2 -VI may be suggested in the growth of AML and ALL blasts. The technique employed in this study allowed measurement of the absolute levels of any mRNA. So it was possible to evaluate the levels of each of the isoforms relative to one another. Results indicated the following rank of magnitude for cPLA 2 in leukemic blasts: PLA 2 -VI4PLA 2 -IVA ¼ PLA 2 -IVB4PLA 2 -IVC. Together, these observations might suggest PLA 2 -VI as a novel and interesting target for drug development for leukemic therapy. However, given the ubiquitous expression of PLA 2 -VI and its role in glycerophospholipid metabolism, drug strategies targeting PLA 2 -VI must exhibit selectivity to avoid undesired side effects.
In another set of experiments we investigated whether mRNAs derived from the nine sPLA 2 genes (i.e PLA 2 -IB, PLA 2 -IIA, PLA 2 -IID, PLA 2 -IIE, PLA 2 -IIF, PLA 2 -III, PLA 2 -V, PLA 2 -X and PLA 2 -XII) were detected in AML and ALL leukemic blasts. PLA 2 -IIE and PLA 2 -III were not present at detectable levels in AML and ALL leukemic blasts and control blood mononuclear cells (data not shown). In contrast transcripts for other sPLA 2 subtypes could be detected (Figure 1, right part) . Results indicated the following rank of magnitude for sPLA 2 in leukemic blasts: PLA 2 -IB4PLA 2 -XII4PLA 2 -X4PLA 2 -IID4 PLA 2 -IIA ¼ PLA 2 -V4PLA2-IIF. Levels of PLA 2 -IB and PLA 2 -X transcripts were higher (P ¼ 0.0001) in AML blasts than in control cells. In contrast PLA 2 -IIA (P ¼ 0.0005), PLA 2 -IID (P ¼ 0.0007) and PLA 2 -V (P ¼ 0.0009) were markedly reduced, whereas PLA 2 -XII and PLA 2 -IIF ones were unchanged. PLA 2 -X transcripts were higher (P ¼ 0.0006) in ALL blasts than in control cells. In contrast PLA 2 -IIA transcripts levels were reduced, (P ¼ 0.001) whereas PLA 2 -IB, PLA 2 -IID, PLA 2 -IIF, PLA 2 -V and PLA 2 -XII ones were unchanged. Such variations of PLA 2 subtypes would be of importance for leukemic patients. Thus, coagulation activation was often observed in patients with acute leukemia. PLA 2 -IIA, PLA 2 -IID and PLA 2 -V, which possess potent anticoagulant activity, 1 are markedly lowered in AML patients suggesting a putative link between PLA 2 activity and coagulation disorders. Bacterial and fungal infections are the major cause of morbidity and mortality in acute leukemic patients. A decreased PLA 2 -IIA activity which has physiologically significant bactericidal activity, 1,2 and a decreased PLA 2 -V one that plays a role in innate immunity against fungal invasion 1,2 might be implicated in these infections. Numerous evidences have highlighted that cytosolic PLA 2 -IVA is the key enzyme for AA release from phospholipids of mammalian cells; AA being the first step for the biosynthesis of eicosanoids. Only those sPLA 2 species that have a high specific activity of phospholipids hydrolysis and that can bind well to phosphatidylcholine-rich membranes, the PLA 2 -V and PLA 2 -X, have the capacity to release fatty acids when added to mammalian cells. As shown in Figure 1 , the increase of PLA 2 -X transcripts in leukemic blasts is higher than the decrease of their PLA 2 -V transcripts. Thus, as lipolytic enzyme, PLA 2 -X might contribute to the generation of lipid mediators. It is interesting that prostaglandin E 2 , a COX metabolite of AA, was recently reported to stimulate the growth of leukemic blasts through an EP 2 receptor-dependent pathway. 4 These results show that mRNA from four out of five cytosolic PLA 2 (PLA 2 -IVA, PLA 2 -IVB, PLA 2 -IVC and PLA 2 -VI) and six out of nine sPLA 2 (PLA 2 -IB, PLA 2 -IIA, PLA 2 -IID, PLA 2 -V, PLA 2 -X and PLA 2 -XII) are present in leukemic blasts, and that their mRNA transcript levels exhibited important variations as compared with blood mononuclear cells (summarized in Table 1 ). One of the more notable finding is that leukemic blasts expressed high amounts of PLA 2 -VI and PLA 2 -X. This could be extremely significant as these two enzymatic activities play a major role in AA release for the generation of COX-and lipoxygenase-derived lipid mediators. In conclusion, these results indicate that immature forms of leukemic AML and ALL blasts have the potential to express multiple isoforms of cPLA 2 and sPLA 2 , which could be of importance given the potential role of these enzyme activities in inflammation, generation of lipidic Table 1 Comparison of soluble PLA 2 and cytosolic PLA 2 transcripts levels in ALL blasts, AML blasts and control blood mononuclear cells The treatment of chronic myeloid leukaemia (CML) with imatinib mesylate (IM, Glivec) results in complete cytogenetic response (CCyR) for most patients in the chronic phase of the disease. For the majority of patients in CCyR, persisting low-level disease is demonstrable by sensitive real-time quantitative PCR (RQ-PCR) for BCR-ABL in peripheral blood. 1 We have shown an IM-resistant, quiescent (G 0 ) population of BCR-ABL þ leukaemic stem cells in primary CD34 þ -selected populations from CML patients at diagnosis that persist following IM treatment in vivo.
2 In contrast, BCR-ABL þ CD34 þ cells that are actively cycling are killed by IM in-vitro. Furthermore, IM seems to exert an antiproliferative effect on the G 0 population leading to accumulation of drug-resistant, quiescent malignant progenitor cells. 2 It is possible that this population is responsible for persistently positive BCR-ABL RQ-PCR and also for the rapid relapse observed in patients in CCyR who cease to undergo IM therapy. 3 To eradicate this population, we hypothesized that a valid strategy might involve a pulsed IM (pIM) schedule plus recombinant granulocytecolony stimulating factor (G-CSF) to push the clonal G 0 population into cell cycle and restore IM sensitivity. In light of these data, we developed a pilot, randomized, three-arm phase II study to determine the safety and toxicity of pIM with or without G-CSF in patients with chronic phase CML who had achieved CCyR (EudraCT 2004-000179-33).
Chronic phase CML patients X18 years of age, already established on IM and having achieved a CCyR (but not a complete molecular response), were eligible for this study. RQ-PCR was performed according to a standard protocol at the Adult Leukaemia Unit, Hammersmith Hospital. 4 At trial entry, patients received IM according to their established dose level (400 mg for all patients). After informed consent was obtained, patients were randomized to receive either Lenograstim (rHu-G-CSF, 263 mg, provided by Chugai Pharma UK and France) on days 24, 26 and 28 of each cycle in combination with pIM (pIM-G) therapy, pIM therapy alone or continuous IM (cIM) therapy alone (IM given at earlier dose level). For the group receiving pIM and pIM-G, IM was continued for days 1-21, and stopped until day 28 of each 4-week cycle. G-CSF was given every 48 h during the IM-free week as preclinical studies had shown a more dramatic effect with pulsed G-CSF compared with continuous G-CSF. 5 The 7-day break in IM therapy was considered long enough for drug and metabolite washout to allow reversal of the antiproliferative effects of IM on leukaemic stem cells, but short enough to be safe from the point-of-view of disease control. Treatment was administered in 4-week cycles up until a maximum of 12 cycles. Monthly BCR-ABL RQ-PCR was performed. The primary end points were: (1) safety of the combination of rHu-G-CSF plus IM. For the purposes of the trial, this was defined as X2 patients in either of the two experimental arms experiencing severe adverse events or Grade 3/4 toxicity (according to National Cancer Institute (NCI) toxicity criteria) attributable to the study treatment, (2) safety of IM interruption, that is, no apparent loss of molecular, CCyR or complete haematological response above that seen in the control arm (proportion of patients progressing). The secondary end point was molecular response to IM interruption þ /À G-CSF.
Between October 2004 and September 2006, 45 patients were recruited to the study as planned (15 in each arm) from five centres in the UK and one in France. The relevant patient characteristics are shown in Table 1 . Non-haematological grade I and II toxicities were in keeping with the known side effect profile of both the study drugs (data not shown). Significantly, more bone pain and arthralgias were observed in the pIM-G arm (P-values 0.018 and 0.009, respectively), almost certainly relating to lenograstim. No haematological toxicity was observed and no grade III or IV toxicities occurred as a result of study treatment. The treatment, therefore, seemed to be well tolerated.
